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Introduction: 
Cognitive deficits are one of the most common causes of mental deterioration 
such as learning impairment, delayed amnesia and memory problems that are the 
debilitating consequences of aging in elderly people. The past three decades have 
witnessed a considerable research effort, directed towards discovering the cause of 
cognitive disorders with the ultimate hope of developing safe and effective 
pharmacological treatments (Corbett et al., 2012). An epidemiological study carried 
out by Ferri et al. (2005) revealed that 24.3 million people are involved with dementia 
with increase of 4.6 million new cases each year; so the number of affected people will 
be doubled every 20 years. The number of the people with dementia in 2010 was 
reported by Alzheimer’s disease International with more than 35 million people 
worldwide (Anonymous a, 2011). Only in USA, an estimated 5.4 million Americans are 
suffering under Alzheimer’s disease in 2012 (Anonymous b, 2012). 
Most presenile dementia conditions caused by aging, such as Alzheimer’s disease 
(AD) are characterized by common psychopathological phenomena (Brewer et al., 
1998). Alzheimer’s disease was identified for the first time about 100 years ago, but 
only since approximately three decades the research is focusing on its symptoms, 
causes, risk factors and treatment.  
The etiology of Alzheimer’s disease and similar illnesses has been partly defined 
and several factors have been suggested to be effective in reduction of the incidence 
of these diseases. Since the improved hypotheses and theories about the etiology of 
these neurological disorders are largely based on epidemiological studies, none of 
them has been completely accepted (Howes and Houghton, 2003). The pathological 
features that have been identified in the central nervous system (CNS) in Alzheimer’s 
disease are senile plaques, neurofibrillary tangles and neurotransmitter disturbances 
(García-Sierra et al., 2012) 
The pathophysiology of Alzheimer´s disease is complex and involves different 
biochemical pathways like a defective beta-amyloid metabolism, inflammatory and 
oxidative processes as well as disordered cholinergic neurotransmission (Welberg, 
2011). It has been well indicated that a consistent neuropathological occurrence 
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associated with memory loss is a cholinergic deficit, which correlates with the severity 
of Alzheimer´s disease (Garcia-Alloza et al., 2006). Thus, attempts to restore 
cholinergic function have been considered as a rational target to improve therapeutics 
used to treat the symptoms of Alzheimer´s disease. The cholinergic function could be 
enhanced by stimulation of cholinergic receptors or prolonging the availability of the 
neurotransmitter acetylcholine (ACh) at cholinergic synapses (Fig. 1). The latter can be 
achieved by using acetylcholinesterase (AChE) inhibitors that block this key enzyme in 
the breakdown of acetylcholine (Howes and Houghton, 2003). 
 
Fig. 1. The function of ACh and AChE in synaptic area (CNS forum.com) 
Recent studies showed that the function of acetylcholinesterase is not limited to 
the termination of cholinergic neurotransmission. It is now clear that the cholinergic 
system is also involved in the regulation of some signal transduction pathways like 
beta-amyloid processing and modulation of regional cerebral blood flow. Concerning 
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this matter the cholinergic therapies as disease-improving agent can have potential as 
one strategy in addition to the classic cholinergic hypothesis, which is limited to 
symptomatic treatment of Alzheimer´s disease (Lane et al., 2004). 
During the last two decades the use of complementary medicines, such as herbal 
medicinal substances in dementia therapy has been studied (Andrade et al., 2000). A 
potential source of acetylcholinesterase inhibitors is certainly provided by several 
plants used in traditional practices of medicine to enhance cognitive functions 
(Mukherjee et al., 2007). As many of people are relying and using the herbal 
preparations based on traditional medicines, the allopathic medicine is encouraged to 
profit and apply the knowledge of these important sources. Using this knowledge, e.g. 
Ginkgo biloba L. (ginkgo) with antioxidant and cholinergic activities has been studied in 
clinical trials and shown global benefit for patients with cognitive disorders. Memory-
improving properties and cholinergic activities have also been showed for extracts 
from Salvia officinalis L. (sage) and Melissa officinalis L. (lemon balm) (Singhal et al., 
2012). Secondly, studies for natural compounds with respective activity have resulted 
e.g. in the identification of galantamine from Galanthus nivalis L. (snowdrop) as a 
potent acetylcholinesterase inhibitor, which today is one therapeutic option in the 
treatment of Alzheimer´s disease (Hostettmann et al., 2006; Prvulovic et al., 2010).  
Iran (formerly called Persia) is located in southwest Asia, within the Middle East 
region and covers a territory of 1,648,195 square kilometers. Iran’s specific 
geographical position makes it unique in the world with its diverse climatic conditions. 
Among its 12 different geographic environments, Iran is divided into 5 major climate 
zones including Mediterranean, desert and half-desert, warm-humid, warm-dry, and 
mountainous areas (Fig. 2). Due to this variety of climate, more than 7500 plant 
species grow in Iran, and for about 1800 of those species a medicinal use is described 
(Adhami et al., 2007). 
In addition, Iran is among those countries with the longest and richest history in 
traditional medicine (TM). The activities and authorships of famous Iranian physicians 
like Avicenna (author of The Canon of Medicine) and Rhazes (author of Al-Hawi) and 
many others, showed brilliantly this claim (Adhami et al., 2007).  
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Fig. 2. Iran climate map (Adhami et al., 2007). 
Some early Iranian physicians were already engaged in the study and treatment of 
cognitive disorders and successfully used different plants to treat these diseases 
(Sharafkandi, 2004). 
To find new herbal compounds with AChE inhibitory effects, drugs which have 
been used in Iranian traditional medicine (ITM) for treatment of cognitive disorders 
seemed a promising source for an in vitro approach. 
In this doctoral project, a bio-activity screening for AChE inhibition was carried out 
on herbal drugs which have been used in ITM for memory loss and enhancement of 
cognitive performance. Then the most active extracts were investigated in detail to 
elucidate the active compounds.  
Methodology overview 
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Methodology overview 
The process of this doctoral project is divided into 2 sections: 
1- Bio-activity screening for AChE inhibitory activity.  
1-1- Selection of promising medicinal plants used for memory loss and 
enhancement of cognitive performance from several authoritative 
written documents of ITM. The respective herbal drugs were obtained 
from herbal shops and identified scientifically. 
1-2- Extraction of 40 selected drugs with dichloromethane and methanol by 
accelerated solvent extraction (3 times with dichloromethane followed 
by 3 times with methanol). The extracts of each solvent were combined 
and evaporated under reduced pressure to obtain 80 extracts.  
1-3- TLC bioautography screening of 80 extracts. Duplicated TLC was carried 
out for each extract. Bioautography assay was performed on one of the 
plates with 1-naphtyl acetate as reagent. The other one was derivatized 
with anisaldehyde-sulfuric acid or other sufficient reagents to 
determine the chemical composition of the extract. In this investigation 
32 extracts showed activity for AChE inhibition. 
1-4- Analyses of the active extracts by colorimetric assay. A quantitative 
microplate assay based on Ellman’s method (Rhee et al., 2001; Adhami 
et al., 2012) was used to quantify the AChE inhibitory activities of the 
substances. The assay was performed in triplicate for every 
concentration and each experiment was repeated 5 times. The most 
active herbal drugs included the seeds from Peganum harmala L., the 
fruit resin from Semecarpus anacardium L., the gum-resin from Dorema 
ammoniacum D. Don and the oleo gum-resin from Ferula gummosa 
Boiss., which were selected for further studies. 
2- Detailed investigation of the most active herbal drugs in 3 steps: 
2-1-  Isolation and structure elucidation of the active compounds.  The active 
compounds of the four active drugs were identified and isolated using 
several chromatographic techniques such as thin layer chromatography 
(TLC), vacuum liquid chromatography (VLC), column chromatography 
Methodology overview 
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(CC), size exclusion chromatography (SEC), solid phase extraction (SPE), 
high performance liquid chromatography (HPLC), counter current 
chromatography (CCC) and automated high performance thin layer 
chromatography (HPTLC). The structures of the active components were 
characterized by one and two-dimensional 
1
H and 
13
C NMR 
spectroscopy and mass spectrometry. 
2-2- Determination of IC50 values for the active compounds. Quantitative 
microplate assay was carried out for different concentrations of each 
extract and active pure compound. Each assay was repeated 3 times. 
2-3- Quantification of the active compounds in the total extracts. The 
content of the active compounds in the four different sources was 
determined by HPLC analyses with external standardization. Each 
analysis was performed in duplicate.  
All methods are explained comprehensively in the respective articles. 
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Results and Conclusion 
All results of the research carried out during this thesis are included in 4 articles: 
1- Adhami HR, Farsam H, Krenn L. Screening of medicinal plants from Iranian 
traditional medicine for acetylcholinesterase inhibition. Phytotherapy Research. 
2011, 25(8): 1148-1152.  
This article contains the results of the screening of 80 extracts of 40 
selected herbal drugs from ITM and the detailed investigation of the seeds 
from Peganum harmala. The screening includes both bioautography and 
microplate assay. This is the first report of AChE inhibition for P. harmala 
that showed the two alkaloids harmine and harmaline are the major AChE 
inhibitory compounds in the seeds of Peganum harmala. In this study, the 
pulverization of all the herbal drugs, extraction, bioautography assay, 
microplate assay as well as HPLC-quantification were performed by the 
author of the thesis.  
2- Adhami HR, Linder T, Kaehlig H, Schuster D, Zehl M, Krenn L. Catechol alkenyls 
from Semecarpus anacardium: acetylcholinesterase inhibition and binding 
mode predictions. Journal of Ethnopharmacology. 2012, 139(1): 142-148.  
This article contains detailed investigation of the fruit resin from Semecarpus 
anacardium. In this study, two catechol alkenyls from this resin were 
isolated and their AChE inhibitory activities were proved for the first time 
and their activities additionally confirmed by an in silico docking experiment. 
A comparison of their inhibitory capacity on AChE versus BChE showed that 
they are selective AChE inhibitors. For this study, extraction, bioautography 
assay, microplate assay, all the chromatographic processes to isolate the 
active compounds and HPLC-quantification were carried out by the first 
author. 
3- Adhami HR, Kaehlig H, Zehl M, Krenn L.  Spiro-sesquiterpenoidic chroman- 
diones from gum ammoniacum with acetylcholinesterase inhibitory activity.  
The manuscript contains the detailed investigation of the gum-resin from 
Dorema ammoniacum. A new and a known spiro-sesquiterpenoidic 
Results and Conclusion 
8 
 
chromadione were proven in this investigation as AChE inhibitors for the 
first time. From the correlation of IC50 values of these two compounds in 
AChE inhibition with their concentrations in gum ammoniacum can be 
concluded that they are among the major AChE inhibitory substances in this 
drug. The manuscript will be submitted to Phytochemistry Letters. In 
detailed investigation of gum ammoniacum, extraction, bioautography 
assay, microplate assay, all the chromatographic steps for the isolation of 
the active components as well as HPLC-quantification were done by the 
author of the thesis. 
4- Adhami HR, Scherer U, Kaehlig H, Hettich T, Schlotterbeck G, Reich E, Krenn L. 
Combination of bioautography with HPTLC-MS/NMR: a fast identification of 
acetylcholinesterase inhibitors from galbanum.  
The manuscript contains the detailed investigation of the oleo gum-resin 
from Ferula gummosa. This study showed the advantage of TLC-MS/NMR as 
a fast method for dereplication in natural compound research. Two 
coumarin derivatives with AChE inhibitory activity were reported for the first 
time in Ferula gummosa. The manuscript will be submitted to the Journal of 
Planar Chromatography. In this investigation, extraction, bioautography 
assay, microplate assay, fractionation of the extract, automated HPTLC, 
extraction of the active zones from HPTLC plates into mass spectrometer 
and for NMR spectroscopy as well as HPLC-quantification were performed by 
the author of the thesis.  
The achieved results confirmed for several known and new compounds that they 
considerably contribute to the effects of their respective drugs and underline the 
plausibility of their use in the treatment of cognitive deficits in Iranian traditional 
medicine. Nevertheless, their activities were not strong enough that they might serve 
as very promising new lead compounds for the development of new therapeutic AChE 
inhibitors. However, it has to be underlined that all herbal drugs investigated in this 
study, even such ones which did not show AChE inhibition might enhance the cognitive 
performance by different mechanisms. 
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TLC bioautography for AChE inhibition was carried out according to Marston et al. 
(2002). Different mobile phases were used for DCM and MeOH extracts (Fig. 1-3). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. The reaction mechanism of AChE inhibition used in bioautography. 
 
Fig. 2. Sample of bioautography for DCM extracts with the non-polar mobile phase CHCl3-EtOAc-MeOH 
(90+7+3). 25: Cuminum cyminum L., 44: Cannabis sativa L., 45: Coriandrum sativum L., R: chelidonine 
(positive control in non-polar system), 48: Sesamum indicum L. 
  
O
O
CH3 OH
CH3COOH
NN NN
MeO
OMe
NN NN
MeO
OMe
OH OH
Acetylcholinesterase
+
1- Naphthyl acetate 1-Naphthol
+ +
2Cl-
Fast Blue Salt (FBS)
Azo dye
(purple)
Supporting information for article 1 
17 
 
Fig. 3. Sample of bioautography for MeOH extracts with the polar mobile phase EtOAc-MeOH-H2O 
(100+13.5+10). 33: Boswellia carterii Birdw., 20: Asarum europaeum L., 39: Commiphora mukul Engl., 
37: Aloe spp.,  R: physostigmine (positive control in polar system), 47: Peganum harmala L., 41: 
Pistacia atlantica Defs., 30: Astragaus arbusculinus Bornm. & Gauba, 43: Anethum graveolens L.  
 
The AChE inhibitory activities of the substances were measured by a quantitative 
colorimetric assay based on Ellman’s method (Rhee et al., 2001) (Fig. 4). 
 
 
Fig. 4. The reaction mechanism of AChE inhibition used for microplate assay. 
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For calibration of the microplate assay 7 different concentrations of physostigmine 
(150, 75, 37.5, 18.75, 9.37, 4.69, 2.34 µg/ml) were used. After adding the enzyme, 6 
different incubation times were examined. Based on the calibration curves, 10 minutes 
was considered as optimum incubation time (Fig. 5-6). 
 
Fig. 5. AChE inhibition of physostigmine in a microplate assay. Columns No. 3-10 related to 
concentrations of 150-1.17 µg/ml. Column No. 2 is the negative control (10% DMSO). 
 
Fig. 6. Calibration curves for AChE inhibition of physostigmine after different incubation times. 
  
Supporting information for article 1 
19 
 
Due to the best activity determined for the extracts from the seeds of Peganum 
harmala this drug was investigated in detail. The active compounds were identified as 
harmaline and harmine (Fig. 7-8).  
 
Fig. 7. Peganum harmala. 1: shrub (http://crwma.co.crook.or.us), 2: flower (http://agri.nv.gov), 3: 
capsules (http://caliban.mpiz-koeln.mpg.de), 4: dried capsules (http://www.madrean.org), 5: seeds.  
 
 
Fig. 8. Structures of harmine and harmaline, the most active compounds for AChE inhibition in seeds of 
Peganum harmala. 
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The IC50 values of the extracts and the two alkaloids for AChE inhibition were 
determined by microplate assay (Fig. 9). 
 
Fig. 9. AChE inhibition of DCM and MeOH extracts (200, 100, 50, 25, 12.5, 6.25, 3.13 µg/ml) and 
harmine and harmaline (30, 15, 7.5, 3.75, 1.87, 0.94 µg/ml). 
 
The concentrations of active compounds in DCM and MeOH extracts were 
determined by HPLC analyses using external standardization (Fig. 10). 
 
Fig. 10. Calibration curves for HPLC-quantification of harmine and harmaline. 
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The fruit resin from Semecarpus anacardium was the second drug investigated in 
detail (Fig. 1). 
 
Fig. 1. Semecarpus anacardium. 1: tree (http://www.hear.org), 2: fruits (http://www.flickr.com/photos/ 
dinesh_valke), 3: dried fruits, 4: fruits resin. 
TLC bioautography was performed on the DCM extract of the fruit resin from 
S. anacardium (Fig. 2). 
Fig. 2. TLC of DCM extract. A: bioautography assay, B: derivatization with anisaldehyde-sulphuric acid. 
1: DCM extract of fruit resin from S. anacardium, 2: chelidonine (positive control). Mobile phase: CHCl3-
EtOAc-MeOH (90+7+3). 
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The active compounds were isolated and purified using several chromatographic  
techniques including VLC, SEC and SPE (Fig. 3-6). 
 
Fig. 3. TLC of fractions A1-A6 after VLC of DCM extract. Stationary phase: silica gel 60, mobile phase: 
CHCl3 (250 ml/fraction). TLC Mobile phase: CHCl3-EtOAc-MeOH (100+7+3). 
 
 
Fig. 4. TLC of fractions B1-B7 after VLC of fraction A4. Stationary phase: silica gel 60, mobile phase: 
100-50% petroleum ether in CHCl3 (100 ml/fraction). TLC Mobile phase: CHCl3-EtOAc-MeOH (90+7+3). 
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Fig. 5. TLC of fractions C1-C4 after SEC of fraction B4. Stationary phase: lipophilic Sephadex LH20, 
mobile phase: MeOH (3 ml/20 min). TLC Mobile phase: CHCl3-EtOAc-MeOH (100+4+1). 
 
 
Fig. 6. TLC of compounds A and B after SPE of fraction C3. Stationary phase: Megaband Elut-C18, 
mobile phase: 70-90% MeOH in water (2.5 ml/min). TLC stationary phase: RP-18, mobile phase: 
MeOH. 
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The structures of the isolated components were characterized by one and two-
dimensional 
1
H and 
13
C NMR spectroscopy and mass spectrometry (Fig. 7-20). 
 
 
Fig. 7. MS spectrum of compound A. 
 
 
Fig. 8. MS spectrum of compound B. 
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Fig. 9. 1H NMR spectrum of compound A. 
 
Fig. 10. 13C NMR spectrum of compound A. 
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Fig. 11. COSY spectrum of compound A. 
 
Fig. 12. HMBC spectrum of compound A. 
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Fig. 13. HSQC spectrum of compound A. 
 
Fig. 14. Band selective HSQC spectrum of compound A. 
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Fig. 15. 1H NMR spectrum of compound B. 
 
Fig. 16. 13C NMR spectrum of compound B. 
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Fig. 17. COSY spectrum of compound B. 
 
Fig. 18. HMBC spectrum of compound B. 
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Fig. 19. HSQC spectrum of compound B. 
 
Fig. 20. Band selective HSQC spectrum of compound B. 
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The IC50 values for AChE inhibition were determined for DCM extract, 
fraction A4 and compounds A and B by microplate assay (Fig. 21-22). 
Fig.21. 1: Comparison of AChE inhibition of the DCM extract and the enriched fraction A4 at a final 
concentration of 100 µg/ml, 2: AChE inhibition of fraction A4 (200, 100, 50, 25, 12.5, 6.3, 3.1, 1.6 µg/ml). 
 
 
Fig. 22. AChE inhibition of compounds A and B (140, 70, 35, 17.5, 8.8, 4.4, 2.2, 1.1 µg/ml). 
 
The concentrations of active compounds in the extract were determined by HPLC 
analyses using external standardization (Fig. 23).  
 
Fig. 23. The calibration curves for HPLC-quantification of compounds A and B. 
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Abstract 
Attempts to restore cholinergic function have been considered as a rational target to 
improve the symptoms of Alzheimer’s disease. One therapeutic option is the use of 
AChE inhibitors. During the last two decade the use of herbal medicinal preparations in 
dementia therapy has been studied based on traditional medicine. Gum ammoniacum 
is the gum-resin from Dorema ammoniacum D. Don which has been used in Unani and 
Iranian traditional medicine for several indications. A previous study had shown AChE 
inhibitory activity for a dichloromethane extract of this resin. The aim of this study was 
the isolation and characterization of the active compounds from gum ammoniacum. 
Extraction of the resin was performed by sonification with dichloromethane. The 
extract was investigated by a respective colorimetric microplate assay and the active 
zones were identified via TLC bioautography and isolated using several 
chromatographic techniques. The structures of the active components were 
characterized by one and two-dimensional 
1
H and 
13
C NMR spectroscopy and mass 
spectrometry as (2'S,5'S)-2'-ethenyl-5'-(3-hydroxy-6-methyl-4-oxohept-5-en-2-yl)-7-
methoxy-2'-methyl-4H-spiro[chromene-3,1'-cyclopentane]-2,4-dione and (2'S,5'R)-2'-
ethenyl-5'-[(2R,4R)-4-hydroxy-6-methyl-3-oxohept-5-en-2-yl]-7-methoxy-2'-methyl-4H-
spiro[chromene-3,1'-cyclopentane]-2,4-dione of which the first one is a new natural 
compound. Their IC50 values for AChE inhibitory activity were 77 and 100 μg/ml, 
respectively. Their concentrations in the resin were determined by HPLC analyses as 
3.1% and 4.6%. 
 
Keywords: Dorema ammoniacum, gum ammoniacum, acetylcholinesterase inhibition, spiro-
sesquiterpenoidic chromadione. 
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1. Introduction  
It is commonly accepted that a cholinergic deficit correlates with the severity of 
Alzheimer’s disease (Garcia-Alloza et al., 2006). Thus, attempts to restore cholinergic 
function have been considered as a rational target to slow down the progress of 
Alzheimer’s disease. One therapeutic option is the use of AChE inhibitors which block 
this key enzyme in the breakdown of acetylcholine (Howes and Houghton, 2003). 
During the last two decades the use of herbal medicinal substances in dementia 
therapy has been studied based on traditional medicine (Andrade et al., 2000). Using 
this knowledge, e.g. galanthamine from Galanthus nivalis L. (snowdrop) has been 
identified as a potent acetylcholinesterase inhibitor, which today is one therapeutic 
option in the treatment of Alzheimer’s disease (Hostettmann et al., 2006). 
Dorema ammoniacum D. Don (Apiaceae) is a perennial plant in Iran, Afghanistan 
and northern India.  The gum-resin, commonly known as gum ammoniacum, which is 
secreted from damaged stems and roots has been traditionally used as an expectorant, 
stimulant and antispasmodic drug in the Unani system of medicine (Rajani et al., 2002). 
It is also used as antihelminitic and for gastrointestinal disorders in Iranian traditional 
medicine (ITM) (Amin, 2005). Some biological activities such as antibacterial and 
vasodilatory effects have been reported for this resin (Rajani et al., 2002; Leaman 
2006). Recently, a low cytotoxic activity was shown for the essential oil from fruits of 
D. ammoniacum (Yousefzadi et al., 2011). Additionally, it is listed in the British herbal 
pharmacopoeia as an antispasmodic and expectorant, and used occasionally for 
chronic bronchitis and persistent coughs (Langenheim, 2003; Anonymous, 1996). 
A previous screening study on selected medicinal plants and plant products used in 
ITM showed AChE inhibitory activity for a dichloromethane (DCM) extract of gum 
ammoniacum (Adhami et al., 2011). The aim of this study was the isolation and 
characterization of active compounds from this gum-resin.  
2. Materials and methods 
2.1- Chemicals and reagents 
AChE from electric eel, 1-naphthyl acetate, 5,5’-dithiobis-(2-nitrobenzoic acid) 
(DTNB), Tris-HCl, bovine serum albumin (BSA) and physostigmine were purchased from 
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Sigma (St. Louis, USA). Acetylthiocholine iodide (ATCI) and chelidonine were obtained 
from Fluka (Buchs, Switzerland). Fast Blue B salt (FBS) and silica gel 60 were from 
Merck (Darmstadt, Germany). Two different buffer systems were used (buffer A: 50 
mM Tris-HCl, pH 7.9 containing 0.1% BSA; buffer B: 50 mM Tris-HCl, pH 7.9 containing 
0.1 M NaCl and 0.02 M MgCl2.6H2O). 
2.2. General 
A Genios microplate reader (Tecan, Salzburg, Austria) was used to measure the 
absorbance. Extraction was performed by sonification in a Branson 3150 ultrasonic 
bath (Dumbury, USA). TLC plates, silicagel 60 F254, were obtained from Merck 
(Darmstadt, Germany) and 96-well microplates PS F-bottom from Greiner Bio-One 
(Frickenhausen, Germany). For LC-MS analyses, the separation was performed on an 
Acclaim 120 C18 column, 2.1 × 150 mm, 3 µm (Dionex, Germering, Germany) and mass 
spectroscopy was carried out on an UltiMate 3000 RSLC-series system (Dionex, 
Germering, Germany) coupled to a 3D quadrupole ion trap mass spectrometer 
equipped with an orthogonal ESI source (HCT, Bruker Daltonics, Bremen, Germany). All 
NMR spectra were recorded on a Bruker Avance DRX 600 spectrometer (Bruker 
BioSpin, Rheinstetten, Germany). A Spectrum HPCCC instrument (Dynamic Extractions, 
Berkshire, UK) was used for high performance counter current chromatography 
(HPCCC). HPLC was performed on a Shimadzu instrument with LC-20AD pump, SPD 
M20A diode array detector and SIL 20AC HT auto-sampler (Kyoto, Japan). 
2.3. Plant material  
The dry gum-resin of D. ammoniacum was purchased from a herbal shop in Tehran, 
Iran, and identified by Dr. Gholamreza Amin at the herbarium of the Faculty of 
Pharmacy, Tehran University of Medical Sciences, Tehran, Iran (voucher number PMP-
804). 
2.4. Extraction 
Twenty grams of the resin were ground and extracted twice by sonification with 
200 ml DCM at 40°C for 1 hour. The extracts were combined and concentrated under 
reduced pressure at 40° C to yield 12.98 g of DCM extract. 
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2.5. TLC bioautography assay  
The DCM extract of gum ammoniacum was examined by TLC on silica plates using 
the mobile phase chloroform-ethylacetate-methanol (90+7+3). Anisaldehyde-sulfuric 
acid was used as detection reagent to determine the chemical composition of the 
extract (Wagner and Blat, 2009). In parallel, a TLC bioautography assay was performed 
for AChE inhibitory activity according to Marston et al., 2002 and Adhami et al., 2011. 
The mobile phase was completely removed under airstream before detection. 
Chelidonine served as a positive control showing RF 0.42 in this TLC system. 
2.6. Microplate assay 
A quantitative colorimetric assay based on Ellman’s method (Rhee et al., 2001; 
Adhami et al., 2012) was used to measure the AChE inhibitory activities of the 
substances. Briefly, in a 96-well plate, 25 µl of 15 mM ATCI, 125 µl of 3 mM DTNB in 
buffer B, 50 µl of buffer A and 25 µl of the extract or the isolated substances (from 
15.6 µg/ml to 2.0 mg/ml in 10% DMSO) were thoroughly mixed and the absorbance 
was read at 405 nm every 15 s for 5 times. Finally 25 µl of AChE (0.22 U/ml in buffer A) 
were added and the plate was incubated at 25°C for 10 minutes. Then the absorbance 
was measured again 8 times every 15 s. A 10% DMSO solution was used as negative 
control. To prevent any increase in absorbance due to the color of the extracts or 
spontaneous hydrolysis of substrate, the absorbance before addition of the enzyme 
was subtracted from the absorbance after adding the enzyme. The assay was repeated 
three times for every concentration. Different concentrations of physostigmine (0.12- 
15 µg/ml as the final concentration) served as a positive control for validation. 
2.7. Isolation and characterization of active compounds 
The first fractionation of 12.0 g DCM extract of gum ammoniacum was performed 
by vacuum liquid chromatography (VLC) with silica gel 60 and chloroform as the 
stationary and the mobile phases, respectively. Fractions with similar chemical 
composition were combined. Twelve collective fractions (A1-A12) were examined by 
TLC bioautography for their AChE inhibitory activity. Further purification of the active 
fraction A4 (4.25 g) by VLC on a silica gel column under gradient elution with 100-50 % 
petroleum ether in chloroform yielded 2.85 g of an active fraction B4. Two grams of 
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fraction B4 were loaded on a silica gel column and eluted with chloroform to obtain 
478 mg of fraction C10. An HPCCC under normal phase elution was carried out on 280 
mg of C10 to obtain two oily active compounds K10 (6.0 mg) and K13 (119 mg). The 
stationary and the mobile phase for HPCCC consisted of hexane, ethylacetate, 
methanol and water at a ratio of 5+1+5+1, respectively. The rotation speed was 1620 
rpm and the fractions 6 ml/min of were collected. 
The separation in LC-MS analysis was carried out at 25°C and a flow rate of 0.5 
ml/min. 0.1% aqueous formic acid and acetonitrile were used as mobile phase A and B, 
respectively. The following gradient program was used: 40% B (0 min), 40% B (2 min), 
and 70% B (32 min). The eluent flow was split roughly 1:8 before the ESI ion source, 
which was operated as follows: capillary voltage: -3.7/+3.5 kV, nebulizer: 26 psi (N2), 
dry gas flow: 9 L/min (N2), and dry temperature: 340 °C. CID spectra were obtained in 
automated data-dependent acquisition (DDA) mode with helium as collision gas, an 
isolation window of 4 Th, and a fragmentation amplitude of 1.0 V.   
Compound K10: (+)ESIMS m/z 427.0 [M+H]
+
; ESIMS
2
 (427.0 ) m/z 408.8 (100), 326.7 
(14); ESIMS
3
 (427.0  408.8 ) m/z 326.7 (100), 298.7 (12), 284.7 (51), 204.6 (19), 
150.7 (13); (-)ESIMS m/z 425.0 [M-H]
-
; ESIMS
2
 (425.0 ) m/z 380.8 (11), 362.8 (16), 
204.6 (100).  
Compound K13: (+)ESIMS m/z 427.0 [M+H]
+
; ESIMS
2
 (427.0 ) m/z 408.8 (100), 258.7 
(11); ESIMS
3
 (427.0  408.8 ) m/z 390.8 (57), 352.7 (38), 334.7 (25), 326.7 (63), 
310.6 (21), 298.7 (14), 284.7 (27), 270.6 (17), 258.6 (100), 240.6 (11), 230.7 (11), 218.6 
(18), 216.7 (15), 204.6 (63), 192.7 (22), 174.8 (11), 150.7 (18); (-)ESIMS m/z 425.0 [M-
H]
-
; ESIMS
2
 (425.0 ) m/z 380.8 (28), 362.8 (15), 256.7 (100), 166.6 (20), 150.7 (24).  
All NMR spectra were recorded on a Bruker Avance DRX 600 NMR spectrometer 
using a 5mm switchable quadruple probe (QNP, 
1
H, 
13
C, 
19
F, 
31
P) with z axis gradients 
and automatic tuning and matching accessory. The resonance frequency for 
1
H NMR 
was 600.13 MHz, for 
13
C NMR 150.92 MHz. All measurements were performed for a 
solution in CDCl3 at 298K. Standard 1D and gradient-enhanced (ge) 2D experiments, 
like double quantum filtered (DQF) COSY, TOCSY, NOESY, HSQC, and HMBC, were used 
as supplied by the manufacturer. Chemical shifts are referenced internally to the 
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residual, non-deuterated solvent signal for 
1
H (δ = 7.26 ppm) or to the carbon signal of 
the solvent for 
13
C (δ = 77.0 ppm). 1H and 13C NMR data are summarized in Table 1. 
 
Table 1 
1H and 13C NMR data of compounds K10 and K13 (CDCl3, 600 MHz) 
 
 
2.8. HPLC  
The DCM extract of gum ammoniacum and the isolated compounds were analyzed 
by HPLC under gradient elution on a Hypersil BDS-C18 column (250×4 mm id) at 35°C. 
The mobile phase consisted of acetonitrile (A) and water (B) at a flow rate of 0.75 
ml/min. After an isocratic step at 50% A for 10 min the concentration of solvent A 
increased up to 80% in 30 min and the elution was kept at this concentration for 
further 5 min. The eluates were monitored at 238 nm.  
  
K10  K13  
Position δC (dept) δH  δC (dept) δH 
2  169.8 (s) ---  168.4 (s) --- 
3   70.8 (s) ---    72.1 (s) --- 
4 191.4(s) ---  189.2 (s) --- 
5 127.9 (d) 7.85 (1H, d, J= 8.8 Hz)  128.6 (d) 7.80 (1H, d, J= 8.8 Hz) 
6 111.7 (d) 6.76 (1H, dd, J= 8.8, 2.4 Hz)  112.2 (d) 6.75 (1H, dd, J= 8.8, 2.4 Hz) 
7 165.5 (s) ---  166.2 (s) --- 
8 100.7 (d) 6.58 (1H, d, J= 2.4 Hz)  100.8 (d) 6.57 (1H, d, J= 2.4 Hz) 
9 156.5 (s) ---  156.3 (s) --- 
10 115.4 (s) ---  113.8 (s) --- 
11   55.8 (q) 3.86 (3H, s)    55.6 (q) 3.88 (3H, s) 
1' 112.9 (t) 
5.07 (1H, dd, J= 17.3, 0.8 Hz) 
5.13 (1H, dd, J= 10.8, 0.8 Hz) 
 115.9 (t) 
4.90 (1H, dd, J= 10.8, 0.7 Hz) 
4.89 (1H, dd, J= 17.3, 0.7 Hz) 
2’ 142.7 (d)  5.96 (1H, dd, J= 17.3, 10.8 Hz)   140.2 (d)  5.60 (1H, dd, J= 17.3, 10.8 Hz) 
3’   56.1 (s)  ---    56.2 (s)  --- 
4’   34.2 (t)  1.86 (2H, m)    35.9 (t)  
2.36 (1H, m) 
1.54 (1H, ddd, J= 12.9, 5.5, 2.7 Hz) 
5’   29.6 (t)  
2.21 (1H, m) 
1.93 (1H, m) 
   28.4 (t) 
2.25 (1H, m)  
1.87 (1H, m) 
6’   49.4 (d)  3.03 (1H, ddd, J= 9.0, 10.5, 10.5 Hz)    46.1 (d) 3.44 (1H, ddd, J= 8.0, 10.4, 10.4 Hz)  
7’   39.7 (d)  1.93 (1H, m)    44.7 (d)  3.03 (1H, qd, J= 7.0, 10.4 Hz)  
8’   79.8 (d)  
3.90 (1H, dd, J= 7.8, 9.6 Hz) 
2.77 (1H: OH, d, J= 7.8 Hz) 
 215.0 (s) --- 
9’ 201.4 (s)  ---    73.9 (d)  
4.69 (1H, br d, J= 9.8 Hz) 
3.41 (1H: OH, br) 
10’ 122.7 (d)  6.01 (1H, sep, J= 1.1 Hz)   120.0 (d) 4.99 (1H, sep d, J= 1.4, 9.8 Hz)  
11’ 158.7 (s) ---  140.3 (s) --- 
12’   28.1 (q) 1.90 (3H, d, J= 1.1 Hz)    26.0 (q) 1.80 (3H, d, J= 1.4 Hz) 
13’   22.2 (q) 0.90 (3H, s)    23.2 (q) 0.98 (3H, d, J= 0.6 Hz) 
14’   16.1 (q) 0.92 (3H, d, J= 6.9 Hz)    15.7 (q) 1.21 (3H, d, J= 7.0 Hz) 
15’   21.4 (q) 2.10 (3H, d, J= 1.1 Hz)    18.5 (q) 2.10 (3H, d, J= 1.4 Hz) 
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3. Result and discussion  
The gum-resin of Dorema ammoniacum has been used in ITM for centuries for 
different indications. There are several herbal mixtures for which a use for memory 
enhancement or treatment of memory loss is described in ITM. As most of these 
herbal preparations contain one or more gum-resins, gum ammoniacum had been 
included in a screening study for AChE inhibition (Adhami et al., 2011). Based on a 
moderate activity of the DCM extract of gum ammoniacum in the mentioned study, 
two active compounds from this gum-resin were isolated and their structures were 
characterized. 
3.1. Isolation of active compounds 
By VLC a very fast enrichment of the active fractions from the extract was 
achieved. Subsequent column chromatography resulted in fraction C10 which 
contained two active compounds as monitored in TLC bioautography. For the final step 
of isolation, HPCCC under use of hexane, ethylacetate, methanol and water at a ratio 
of 5+1+5+1 in normal phase elution was applied which yielded two oily active 
compounds (K10 and K13). The distribution ratio of C10 for this solvent system was 
0.68.  
3.2. Identification of active compounds 
ESI-MS resulted in a molecular weight of 426.0 Da for both compounds K10 and 
K13 which is in agreement with the molecular formula of C25H30O6. In positive ion 
mode ESI-MS
3
 spectra major fragment ions were determined at m/z 326.7 and 258.7 
for K10 and K13, respectively. The 
1
H- and 
13
C NMR data proved K10 to be (2'S,5'S)-2'-
ethenyl-5'-(3-hydroxy-6-methyl-4-oxohept-5-en-2-yl)-7-methoxy-2'-methyl-4H-spiro 
[chromene-3,1'-cyclopentane]-2,4-dione and K13 as (2'S,5'R)-2'-ethenyl-5'-[(2R,4R)-4-
hydroxy-6-methyl-3-oxohept-5-en-2-yl]-7-methoxy-2'-methyl-4H-spiro[chromene-3,1'-
cyclopentane]-2,4-dione (Doremon A). The structure of K13 is largely in agreement 
with earlier reports (Arnone et al., 1991) while K10 is a new natural substance 
reported for the first time (Fig 1). 
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Fig.1. Structure of active compounds, left: K10, right: K13 (Doremon A) 
 
The detailed 
1
H and 
13
C NMR analyses from compound K13 together with 
numerous connectivities derived from 2D NMR spectra like COSY, TOCSY NOESY, 
HSQC, es well as HMBC results in the structure of a spiro-sesquiterpenoidic chroman-
2,4-dione derivative, which is known as doremone A in the literature (Arnone et al., 
1991). All 
1
H as well as 
13
C chemical shifts (Table 1) match exactly with the published 
data. The relative stereochemistry at carbon 3’ and 6’ could be confirmed by a NOESY 
crosspeak from H-6’ to the methyl group 13’. The configuration of the stereocentres 7’ 
and 9’ were proven by comparing the NMR data with those of the acetylated 
doremone A given by Appendino et al. (Appendino et al., 1991), who in addition 
published a X-ray structure of the 3’ racemic mixture of acetyldoremone A.  
The NMR spectra of K10 revealed a lot of similarities to that of K13. All 
1
H and 
13
C 
NMR signals for the 7-methoxy-chroman-2,4-dione part showed almost the same 
chemical shifts including the spirane carbon with its very characteristic downfield shift 
to about 72 ppm. All other NMR signals varied from K13, most predominantly in the 
sidechain. The 
13
C ppm value of the ketone shifts from 215 ppm in doremon A for 
almost 14 ppm to 201.4 ppm in K10 was indicative for a conjugation with the double 
bond. The corresponding olefinic proton 10’ in K10 is 1 ppm deshielded in the 
1
H NMR 
compared to K13 showing a septett multiplicity due to the allylic coupling with the two 
methyl groups only. The vicinal coupling as in K13 is lost. The methyl protons 14’ in K10 
give a HMBC correlation to C-8’, which is a CH signal bearing an alcohol functionality 
due to a carbon shift of 79.8 ppm and a 
1
H shift of the attached proton of 3.90 ppm. As 
a result, these differences in the NMR spectra of the two compounds prove that the 
ketone 8’ and the alcohol at 9’ in doremon A have switched their positions in K10, so 
that the carbonyl 9’ is now in conjugation with the double bond and the alcohol has 
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moved to 8’ (Fig. 1). The stereochemistry of these two centers remains undefined. The 
small shift variations in the cyclopentane part are not only due to the altered 
sidechain, a NOESY crosspeak between H-6’ and the olefinic H-2’ reveals a change in 
the relative configuration of the stereocentres 3’ and 6’ compared to doremone A 
(Fig. 1). 
3.2. AChE inhibition 
The AChE inhibitory activity of the DCM extract and the isolated compounds was 
determined for the first time in a microplate assay. The final tested concentrations of 
the samples ranged from 1.56 to 200 µg/ml. The IC50 values for AChE inhibition were 
668 ± 3.12 µg/ml for the extract, 77.14 ± 3.75 µg/ml (181 µM) for K10 and 100.82 ± 
5.14 µg/ml (236 µM) for K13.  
3.3. Quantification of K10 and K13 
HPLC analyses were performed for the quantification of K10 and K13 in the tested 
extract and gum ammoniacum. Several HPLC conditions under variation of the mobile 
phase, flow rate and elution gradient were examined to optimize the HPLC separation 
for K10, K13 and the DCM extract. The concentration of the two active compounds was 
determined by external standardization. The peak areas of both compounds were 
linearly dependent on concentrations over the selected range with correlation 
coefficients of R
2
= 0.9869 for K10 and R
2
= 0.9837 for K13. The concentrations of K10 
and K13 in the DCM extract were determined as 5.8% and 8.4%, respectively. Total 
amounts of these two components in gum ammoniacum were 3.1% K10 and 4.6% K13. 
Conclusion 
A new and a known spiro-sesquiterpenoidic chromadione were isolated and their 
activity on AChE inhibition determined for the first time. From the correlation of their 
IC50 values for AChE inhibitory activity with their concentrations in gum ammoniacum 
can be concluded that they are among the major substances responsible for AChE 
inhibition in this drug. Due to these results the use of this drug in ITM in mixtures 
improving cognitive functions seems plausible. 
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The gum-resin from Dorema ammoniacum (gum ammoniacum) was investigated 
in detail as the third active drug in this thesis (Fig. 1).  
 
Fig. 1. Dorema ammoniacum. 1: shrub (http://davesgarden.com), 2: gum-resin. 
 
The active zones were identified by a TLC bioautography of the DCM extract of 
gum ammoniacum (Fig. 2). 
 
Fig. 2. TLC of DCM extract. 1: bioautography with 1-naphtyl acetate reagent, 2: derivatization with 
anisaldehyde-sufuric acid. Mobile phase CHCl3-EtOAc-MeOH (90+7+3). 
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The active compounds were isolated using several chromatographic 
methods including VLC, CC, HPCCC (fig. 3-7). 
 
Fig. 3. TLC of fractions A1-A12 after VLC of DCM extract on a silicagel 60 column under elution with 
chloroform. TLC mobile phase: CHCl3-EtOAc-MeOH (100+7+3). Reagent: anisaldehyde-sulfuric acid. 
 
 
Fig. 4. TLC bioautography of fractions A1-A12. TLC mobile phase: CHCl3-EtOAc-MeOH (100+7+3). 
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Fig. 5. TLC of fractions B1-B5 after VLC of fraction A4 under gradient elution with 100-50 % petroleum 
ether in chloroform. TLC mobile phase: CHCl3-EtOAc-MeOH (100+3+1).   
 
 
 
Fig. 6. TLC of fractions C6-C13 after CC of fraction B4 on silicagel 60 under elution with chloroform. 
TLC mobile phase: CHCl3-EtOAc-MeOH (110+4+1). 
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Fig. 7. TLC of the fractions K1-K16 after HPCCC of fraction C10 under normal phase elution with 
hexan-EtOAc-MeOH-H2O (5+1+5+1). K10 and K13 were characterized as active compounds. 
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The structures of the active components were characterized by one 
and two-dimensional 
1
H and 
13
C NMR spectroscopy and mass spectrometry 
(Fig. 8-21). 
Fig. 8. MS spectrum of K10 with the structure of main fragments. 
 
 
Fig. 9. MS spectrum of K13 with the structure of main fragments. 
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Fig. 10. 1H NMR spectrum of K10. 
Fig. 11. 13C NMR spectrum of K10. 
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Fig. 12. COSY spectrum of K10. 
Fig. 13. HMBC spectrum of K10. 
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Fig. 14. HSQC spectrum of K10. 
Fig. 15. NOESY spectrum of K10. 
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Fig. 16. 1H NMR spectrum of K13. 
Fig. 17. 13C NMR spectrum of K13. 
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Fig. 18. COSY spectrum of K13. 
Fig. 19. HMBC spectrum of K13. 
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Fig. 20. HSQC spectrum of K13. 
Fig. 21. NOESY spectrum of K13. 
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The IC50 values of DCM extract and the active compounds for AChE inhibition 
were determined in the microplate colorimetric assay (Fig. 22). 
 
Fig. 22. AChE inhibition of DCM extract, K10 and K13 (200, 100, 50, 25, 12.5, 6.25, 3.12 µg/ml).  
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In addition, the concentrations of the active components in gum 
ammoniacum were determined by HPLC analyses using external standardization 
(Fig. 23-24) 
 
Fig. 23. HPLC chromatogram of the DCM extract from gum ammoniacum. 
 
 
Fig. 24. Calibration curves for HPLC-quantification of K10 and K13. 
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Abstract 
In the search for new natural compounds with acetylcholinesterase (AChE) inhibitory 
activity, this study focused on galbanum, the oleo gum-resin from Ferula gummosa 
Boiss. which had shown AChE inhibitory activity in a screening. The isolation of bio-
active compounds from plant extracts usually is laborious and time-consuming. Thus, 
for fast identification of active compounds, HPTLC bioautography was combined with 
HPTLC-MS/NMR. After pre-fractionation of the dichloromethane extract by vacuum 
liquid chromatography, fractions were separated by automated HPTLC and active 
zones determined by bioautography. A TLC-MS interface was used to elute the single 
zones from the plates directly into the mass spectrometer. In addition, the two major 
active zones were extracted via the interface HPTLC plates for one and two-
dimensional 
1
H and 
13
C NMR spectroscopy and Q-TOF mass spectrometry. The 
extracted compounds were identified as 7-{[(2E)-3,7-dimethylocta-2,6-dien-1-
yl]oxy}-2H-chromen-2-one (auraptene) and 7-(((1R,4aR,6S,8aS)-6-hydroxy-
5,5,8a-trimethyl-2-methylen edecahydronaphthalen-1-yl)methoxy)-2H-chromen-2-
one (farnesiferol A). This is the first report of auraptene and farnesiferol A in Ferula 
gummosa. Their IC50 values for acetylcholinesterase inhibition were determined for the 
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first time as 47 and 17 µg/ml, and the concentrations of these compounds in galbanum 
were quantified by HPLC analyses as 3.5% and 7.9%, respectively. 
 
Keywords: Galbanum, Ferula gummosa Boiss., acetylcholinesterase inhibition, HPTLC-MS. 
 
1. Introduction 
The correlation of cholinergic deficit with aggravation of Alzheimer’s disease has 
been commonly accepted (Garcia-Alloza et al., 2006). Thus, to slow down the 
symptoms of Alzheimer’s disease, restoration of the cholinergic function has been 
considered as a treatment option. The use of AChE inhibitors is one therapeutic option 
which blocks this key enzyme in the breakdown the acetylcholine (Howes and 
Houghton, 2003). 
Based on traditional medicine, the use of herbal medicinal substances for the 
treatment of dementia has been studied during the last two decades (Andrade et al., 
2000). Using this knowledge, e.g. galantamine from Galanthus nivalis L. (snowdrop) 
has been identified as a potent acetylcholinesterase inhibitor, which today is one 
therapeutic option in the treatment of Alzheimer’s disease (Hostettmann et al., 2006). 
Galbanum is an oleo gum-resin from Ferula gummosa Boiss. (Apiaceae) which is a 
perennial plant indigenous to central Asia, growing in the northern and western parts 
of Iran. F. gummosa (Bārije in Persian) is an Iranian medicinal plant and has been used 
as a tonic, and in epilepsy and chorea (Zargari, 1997). Additionally it has been used for 
gastrointestinal disorders and as a wound-healing remedy in Iranian traditional 
medicine (ITM) (Amin, 2005). For extracts from different parts of F. gummosa several 
biological activities have been demonstrated in recent investigations including 
antibacterial (Abedi et al., 2008), antioxidant (Nabavi et al., 2010), anticonvulsant 
(Sayyah et al., 2002), spasmolytic (Sadraei et al., 2001) and antiepileptic activities 
(Sayyah et al., 2001). 
Extracts from medicinal plants are very complex, thus isolation and structural 
characterization of the active compounds is often an extremely laborious and time-
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consuming process. Thus, finding a fast and reliable method for dereplication of active 
compounds is always one of the major targets in medicinal plant research. 
A bioactivity-guided screening showed AChE inhibitory activity for a dichloro- 
methane (DCM) extract from galbanum (Adhami et al., 2011). In the study presented 
here, HPTLC bioautography was combined with HPTLC-MS/NMR for the very fast 
dereplication of compounds active on AChE inhibition in galbanum.  
2. Materials and Methods 
2.1. Chemicals and reagents 
AChE from electric eel, 1-naphthyl acetate, 5,5’-dithiobis-(2-nitrobenzoic acid) 
(DTNB), Tris-HCl, bovine serum albumin (BSA) and physostigmine were purchased from 
Sigma (St. Louis, USA). Acetylthiocholine iodide (ATCI) and chelidonine were obtained 
from Fluka (Buchs, Switzerland). Fast Blue B salt (FBS) and silica gel 60 were from 
Merck (Darmstadt, Germany). Two different buffer systems were used (buffer A: 50 
mM Tris-HCl, pH 7.9 containing 0.1% BSA; buffer B: 50 mM Tris-HCl, pH 7.9 containing 
0.1 M NaCl and 0.02 M MgCl2.6H2O). 
2.2. General 
Automatic TLC sampler (ATS 4) and automatic developing chamber (ADC 2) from 
Camag (Muttenz, Switzerland) were used for automated HPTLC. TLC visualizer, TLC 
scanner 4, chromatogram immersion device for derivatization, TLC plate heater and 
TLC-MS interface were also from Camag. The absorbance was measured in a Genios 
microplate reader (Tecan, Salzburg, Austria). Extraction was performed by sonification 
in a Branson 3150 ultrasonic bath (Dumbury, USA). TLC and HPTLC plate silicagel 60 
F254 were obtained from Merck (Darmstadt, Germany) and 96-well microplates PS F-
bottom from Greiner Bio-One (Frickenhausen, Germany). For TLC-MS, a pump of HPLC 
Agilent 1260 (Agilent Technologies, Santa Clara, USA) and a single quadrupole Agilent 
6120 mass spectrometer were used. ESI Q-TOF experiments were performed on an 
Agilent Q-TOF 6540 mass spectrometer equipped with an Agilent UHPLC 1290 System. 
Two NMR spectrometers from Bruker (Bruker BioSpin, Rheinstetten, Germany) were 
used for NMR spectra; a 400MHz Bruker Avance II instrument, equipped with a 5mm 
BBO probe and controlled by TOPSPIN 2.1., and a Bruker Avance DRX 600 
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spectrometer operating at 600.13 and 150.90 MHz for 
1
H and 
13
C, respectively, at a 
temperature of 298 K using a triple resonance probe (
1
H, 
13
C, broad band) with triple 
axis pulsed field gradients. HPLC was performed on a Shimadzu instrument with LC-
20AD pump, SPD M20A diode array detector and SIL 20AC HT auto-sampler (Kyoto, 
Japan). A EZ-2plus evaporator from Genevac (New York, USA) was used to evaporate 
the solvents. 
2.3. Plant material  
Galbanum was obtained from a herbal shop in Tehran, Iran, and identified by Dr. 
Gholamreza Amin at the herbarium of the Faculty of Pharmacy, Tehran University of 
Medical Sciences, Tehran, Iran (voucher number PMP-807). 
2.4. Extraction 
Thirty grams of galbanum were stirred with 200 ml DCM at room temperature over 
the night, followed by sonification at 40°C for 30 min. The extract was concentrated 
under reduced pressure at 40°C to yield 17.34 g of a viscous residue. 
2.5. Bioautography assay  
Duplicated TLC was carried out on the DCM extract of galbanum using the mobile 
phase chloroform-ethylacetate-methanol (90+7+3). The solvent was completely 
removed under airstream. A bioautography assay was performed on one of the plates 
according to Marston et al., 2002 and Adhami et al., 2011 to detect the zones active 
for AChE inhibition. The other one was derivatized with anisaldehyde-sulfuric acid. 
Chelidonine served as a positive control showing RF 0.42 in this TLC system. 
2.6. Microplate assay 
The AChE inhibitory activities of the substances were measured by a quantitative 
colorimetric assay based on Ellman’s method (Rhee et al., 2001; Adhami et al., 2012). 
In a 96-well plate, 25 µl of 7.5 mM ATCI, 125 µl of 1.5 mM DTNB in buffer B, 50 µl of 
buffer A and 25 µl of the extract or the isolated substances (from 7.8 µg/ml to 1.0 
mg/ml in 10% DMSO) were thoroughly mixed and the absorbance was read at 405 nm 
5 times every 15 s. After adding 25 µl of AChE (0.11 U/ml in buffer A) the plate was 
incubated at 25°C for 10 minutes and the absorbance was measured again every 15 s 
for 8 times. A solution including 10% DMSO was used as negative control. To prevent 
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any increase in absorbance due to the color of the substances or spontaneous 
hydrolysis of substrate, the absorbance before addition of the enzyme was subtracted 
from the absorbance after adding the enzyme. The assay was repeated three times for 
every concentration. The validation for a positive control was served by different 
concentrations of physostigmine (15-0.12 µl/ml as the final concentration). 
2.7. Fractionation and optimization of HPTLC 
The fractionation of 17 grams DCM extract of galbanum was started by vacuum 
liquid chromatography (VLC). Silica gel 60 was used as the stationary phase under 
gradient elution with chloroform and hexane (20-100%) as the mobile phase. Fractions 
with similar chemical composition were combined to obtain ten collective fractions 
(A1-A10). Automated HPTLC was used to optimize the separation of the fractions A5 
and A6 which contained the most active zones. 
The mobile phase was individually optimized for each fraction according to the 
published guideline (Reich and Schibli, 2006). In the first step each fraction was 
examined by HPTLC with single solvent mobile phases.  Then multiple solvent mobile 
phases were prepared based on the solvent strength which affects the RF value of the 
analyte and the selectivity which affects the relative position of the zones. The mobile 
phases were modified another time to obtain the optimum mobile phase (Fig. 1).  
Fig.1. HPTLC of fractions A5 and A6. 1: HPTLC of A5 and A6 with the mobile phase CHCl3-EtOAc-
MeOH (100+10+2), 2: A5 with the optimum mobile phase CHCl3-MeOH (99+1), 3: A6 with the optimum 
mobile phase CHCl3-EtOAc-MeOH (95+10+2). 
For detection of the fluorescent compounds a TLC scanner was used. Based on the 
optimized separation of the zones in fractions A5 and A6, the zones 1 to 6 which 
showed activity in the assay on AChE inhibition were selected for HPTLC-MS (Fig. 1). 
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2.8. HPTLC-MS 
For HPTLC-MS, the interface was connected between a pump and the mass 
spectrometer. The round and oval extraction head were used for extraction of the 
different zones. Methanol as the solvent and APCI as the ionization method showed 
optimum spectra. Charging high voltage was 2000 V with a nebulizer pressure of 20 
psig. The molecular weights of the zones are listed in table 1. 
 
Table 1 
The molecular weights of active zones obtained from HPTLC-MS 
Fr. A5  Fr. A6 
Zone MW (Da) Zone MW (Da) 
1 
2 
 
 
 
 
298.3 
296.2 
 
 
 
 
 1 
2 
3 
4 
5 
6 
298.3 
296.2 
364.3 
364.3 
382.3 
382.3 
 
2.9. Isolation and characterization of active compounds 
To extract the active zones 1 to 6, the TLC-MS interface was used. The eluate of 
each zone was collected instead of analysis in the mass spectrometer. Methanol was 
the eluent with the flow rate of 0.4 ml/min. Each extraction was carried out in 40 
seconds. The extracted solution of each zone was concentrated by a Genevac 
evaporator and the residues (from 200 to 400 µg) were used for HPTLC (Fig. 2). 
 
 
Fig. 2. HPTLC of isolated zones under UV 366 nm. Mobile phase: CHCl3-EtOAc-MeOH (100+10+2). 
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Due to the highest yield and purity based on TLC scanning, zones 1 and 6 from the 
fractions A5 and A6, respectively, were selected for further investigation. The 
extraction of these two zones was continued to obtain sufficient amounts for NMR 
spectroscopy and determination of the biological activity. Finally 1.58 and 1.75 mg of 
the substances 1 and 6 were obtained, respectively. The structures of the active 
compounds were characterized by one and two-dimensional 
1
H and 
13
C NMR 
spectroscopy and mass spectrometry. The accurate molecular weights of the two oily 
substances were identified by a UHPLC-QTOF MS. A flow injection analysis was 
performed with 0.3 µL sample solution and a flow rate of the mobile phase at 0.4 
ml/min in an isocratic mode. The mobile phase consisted of acetonitrile-water (80:20 
v/v) with 0.1% formic acid. The mass data were acquired in the positive mode, with 
targeted MS/MS at 4 scans. The Agilent Jet Stream ESI-Source was set at 300 °C with a 
drying gas flow at 8 l/min and a nebulizer pressure about 35 psi. The nitrogen sheath 
gas flow was kept at 8 l/min at 300°C. The capillary voltage was set about 3000 V with 
a nozzle voltage of 1000 V and the fragmentor voltage of 100 V. As collision gas 
nitrogen was used by collision energy of about 5 V. 
Compound 1: (+)ESIMS m/z 299.1626 [M+H]
+
; ESIMS
2
 (299.1626 ) (m/z, rel. 
Intensity%): 299.16 (8), 163.04 (100), 137.13 (14). 
Compound 6: (+)ESIMS m/z 383.2221 [M+H]
+
; ESIMS
2
 (383.2221 ) (m/z, rel. 
Intensity%): 383.22 (100), 365.21 (56), 203.18 (87), 163.04 (46), 147.12 (15). 
For subsequent NMR measurement of compound 1 a 400MHz Bruker Avance II 
instrument, equipped with a 5mm BBO probe and controlled by TOPSPIN 2.1. was 
used. In 
1
H spectra standard 1D proton spectra were acquired with a pulse angle of 
30°. Exponential line broadening of 0.3 Hz was applied prior to Fourier transformation. 
A standard 
13
C pulse program from the vendor’s library was used for 
13
C spectra. The 
acquired data were treated with an exponential window function and a line 
broadening of 1 Hz. To determine 
1
H
1
H COSY spectra, a standard pulse program for 
COSY experiments from the vendor’s library was used with gradient, multiple quantum 
filter and no decoupling. The transmitter frequency offset was set to 3.75 ppm. A 
gradient echo-antiecho HSQC pulse sequence from the vendor’s library was employed 
for 
1
H
13
C HSQC spectra. To obtain 
1
H
13
C HMBC spectra, a standard pulse program for 
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HMBC experiment from the vendor’s library with gradient, low-pass J-filter, absolute 
value mode and no decoupling was used. The transmitter frequency offsets were set 
to 3.74 and 105 ppm for 
1
H and 
13
C, respectively. All the two-dimentional data were 
treated with a squared sinus window function in both dimensions. 
All NMR spectra for compound 6 were recorded on a Bruker Avance DRX 600 NMR 
spectrometer using a 5mm switchable quadruple probe (QNP, 
1
H, 
13
C, 
19
F, 
31
P) with z 
axis gradients and automatic tuning and matching accessory. The resonance frequency 
for 
1
H NMR was 600.13 MHz, for 
13
C NMR 150.92 MHz. All measurements were 
performed for a solution in CDCl3 at 298K. Standard 1D and gradient-enhanced (ge) 2D 
experiments, like double quantum filtered (DQF) COSY, TOCSY, NOESY, HSQC, and 
HMBC, were used as supplied by the manufacturer. Chemical shifts are referenced 
internally to the residual, non-deuterated solvent signal for 
1
H (δ = 7.26 ppm) or to the 
carbon signal of the solvent for 
13
C (δ = 77.0 ppm). 
The NMR data of the two compounds are summarized in table 2. 
2.10. HPLC 
The DCM extract of galbanum and the isolated compounds 1 and 6 were analyzed 
by HPLC under gradient elution on a Hypersil BDS-C18 column (250×4 mm id) at 60°C. 
The mobile phase consisted of acetonitrile (A) and water (B) at a flow rate of 0.75 
ml/min. After an isocratic step at 30% A for 5 min the concentration of solvent A 
increased up to 80% in 30 min and the elution was kept at this concentration for 
further 5 min. The eluents were monitored at 322 nm.  
3. Result and discussion  
A major challenge in medicinal plant research is the limitation of available time, 
especially in isolation and characterization of natural compounds which is a time 
consuming process. Combination of bioautography with HPTLC/MS is a fast method for 
the identification of compounds that show bio-activity via a respective assay. 
Compounds are separated on TLC plates and the respective zones are eluted via a 
special interface into the mass spectrometer or extracted for NMR spectroscopy or 
further analysis. 
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Table 2 
1H and 13C NMR data of compounds 1 and 6. 
Compound 1 (CDCl3, 400 MHz) 
 Compound 6 (CDCl3, 600 MHz) 
Position δC (dept) δH 
 Position δC (dept) δH 
2 161.3 (s) ---  2  161.2 (s) --- 
3 113.0 (d) 6.25 (1H, d, J= 9.3 Hz)  3 113.0 (d) 6.25 (1H, d, J= 9.4 Hz) 
4 143.4(d) 7.76 (1H, d, J= 9.3 Hz)  4 143.4 (d) 7.63 (1H, d, J= 9.4Hz) 
4a 124.4 (s) ---  4a 112.5 (s) --- 
5 128.7 (d) 7.36 (1H, d, J= 8.6 Hz)  5 128.7 (d) 7.35 (1H, d, J= 2.5 Hz) 
6 113.3 (d) 6.85 (1H, dd, J= 8.3, 2.3 Hz)  6 113.3 (d) 6.81 (1H, dd, J= 8.4, 2.4 Hz) 
7 162.2 (s) ---  7 162.0 (s) --- 
8 101.6 (d) 6.82 (1H, d, J= 2.5 Hz)  8 101.6 (d) 6.80 (1H, d, J= 2.4 Hz) 
8a 155.9 (s) ---  8a 155.9 (s) --- 
1'   65.5 (t) 4.61 (2H, d, J= 6.6 Hz)  1'   56.6 (t) 2.21 (1H, dd, J= 6.3, 5.8 Hz) 
2’ 118.4 (d)  5.47 (1H, qd, J= 6.6, 1.3 Hz)   2’ 146.6 (s) --- 
3’ 142.4 (s)  --- 
 3’eq 
    ax 
  32.3 (t) 
2.34 (1H, m) 
2.07 (1H, m) 
4’   39.5 (t)  2.10 (2H, m) 
 4’eq 
    ax 
  23.0 (t) 
1.73 (1H, m) 
1.43 (1H, m) 
5’   26.3 (t)  2.10 (2H, m)  4a’   46.2 (d) 1.31 (1H, dd, J= 12.6, 3.0 Hz) 
6’ 123.6 (d)  5.08 (1H, m)  5’   39.0 (s) --- 
7’ 132.0 (s)  ---  6’   79.1 (d) 3.26 (1H, m) 
8’   25.7 (q)  1.67 (3H, d, J= 1.0 Hz)  7’   27.6 (t) 1.70 (1H, m) 
9’ 16.8 (q)  1.76 (1H, s) 
 8’ax 
   eq 
  34.8 (t) 
1.63 (1H, m) 
1.37 (1H, m) 
10’ 17.7 (q)  1.60 (1H, s)   8a’   37.7 (d) --- 
   
 
9’   68.0 (t) 
4.29 (1H, dd, J= 9.5, 5.8 Hz) 
4.02 (1H, dd, J= 9.8, 6.3 Hz) 
   
 10’b 
      a 
111.3 (t) 
4.82 (1H, dd, J= 2.1, 2.1 Hz) 
4.73 (1H, dd, J= 2.1, 1.9 Hz) 
    11’   15.7 (q) 0.82 (3H, s) 
    12’   28.5 (q) 1.05 (3H, s) 
    13’   22.1 (q) 1.00 (3H, d, J= 0.7 Hz) 
 
Galbanum, which has been used for different indications in ITM, showed several 
zones active in AChE inhibition via bioautography assay. Thus, this study aimed to 
extract and identify the active compounds by HPTLC-MS/NMR.  
3.1. Optimization of HPTLC 
HPTLC optimization is a crucial step and was carried out by automated 
instrumentation. This way very distinct and accurate zones were achieved which 
allowed precise extraction of each single compound. In cases where the total extract 
shows a very complex pattern, a primary fractionation by other chromatographic 
methods might be required.  
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3.2. Structure elucidation 
The active zones 1 and 6 from fractions A5 and A6, respectively, were extracted 
from HPTLC plates for structure elucidation. The fractions A5 and A6 were applied on 
HPTLC plates as 16 cm line with concentrations of 5.0 µg/mm. To obtain sufficient 
amounts for NMR and the in vitro assay, 10 HPTLC plates from each fraction were 
developped. 
Q-TOF MS resulted in very accurate molecular weights of 299.1626 Da and 
383.2221 Da for compounds 1 and 6, respectively, which are in agreement with the 
molecular formulae of C19H22O3 and C24H30O4. Comparison of all NMR data proved 
component 1 and 6 as 7-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-2H-chromen-2-one 
(auraptene) and 7-(((1R,4aR,6S,8aS)-6-hydroxy-5,5,8a-trimethyl-2-methylenedeca 
hydronaphthalen-1-yl)methoxy)-2H-chromen-2-one (farnesiferol A), respectively (Fig. 
3). This is the first report of aurapten and farnesiferol A in Ferula gummosa. The NMR 
data for auraptene are in agreement with previous reports (Abulrob et al., 2004). For 
farnesiferol A which is a very rare natural compound only known from few Ferula 
species there is only proton NMR available in literature which is largely in conformity 
with presented data (Hofer et al., 1984). The assignments of all 
13
C shifts were 
determined in detail.   
 
 
 
Fig. 3. The structures of auraptene (1) and farnesiferol A (2). 
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3.3. AChE inhibition 
For the first time an in vitro examination of the AChE inhibitory effect of galbanum 
was performed. The IC50 value of the DCM extract was determined as 88.44 µg/ml. The 
major active compounds isolated in a bioactivity guided approach were auraptene and 
farnesiferol A showing IC50 values of 47.49 µg/ml (159 µM) and 17.63 (46.2 µM), 
respectively. Recently, low AChE inhibitory activities were reported for auraptene and 
farnesiferol A by Karimi et al. (2010), while this study showed much higer activity for 
them in AChE inhibition. This difference might be due to the different sources of AChE. 
In this study AChE was from electric eel, while Karimi et.al. (2010) had used human red 
blood cell AChE.  
3.4. Quantification 
The content of the active compounds auraptene and farnesiferol A in the extract 
was determined by HPLC analyses with external standardization (Fig. 4). Over the 
selected range peak areas of both analytes were linearly dependent on concentrations 
with correlation coefficients of R
2
= 0.9951 for auraptene and R
2
= 0.9978 for 
farnesiferol A. Their concentrations in DCM extract were 6.1% and 13.7%, respectively. 
The total amounts in galbanum were 3.5% auraptene and 7.9% farnesiferol A. 
Fig. 4. HPLC chromatogram of the DCM extract from galbanum. 
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4. Conclusion 
The study showed that HPTLC-MS/NMR can be considered as a fast method for 
dereplication of natural compounds, when an optimum separation on HPTLC plate is 
provided. From the correlation of the concentration of elucidated compounds and 
their IC50 values for AChE inhibition, it can be concluded that auraptene and 
farnesiferol A are of the major responsible compounds in galbanum for this bio-
activity. 
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Galbanum, the oleo gum-resin from Ferula gummosa was the fourth herbal drug 
investigated in detail (Fig. 1).  
 
Fig. 1. Ferula gummosa. 1: shrub (http://yakhaar.ir), 2: oleo gum-resin. 
A TLC bioautography assay for AChE inhibition on DCM extract of galbanum 
presented several active zones which showed strong UV absorbance in 366 nm (Fig. 2). 
 
Fig. 2. TLC of the DCM extract. 1: UV 366 nm, 2: bioautography with 1-naphtyl acetate reagent, 3: 
derivatization with anisaldehyde-sufuric acid. Mobile phase: CHCl3-EtOAc-MeOH (90+7+3). 
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As the DCM extract of galbanum was very complex, a primary fractionation was 
performed by VLC to obtain 10 collective fractions.  Then the isolation of the fractions 
A5 and A6 which included the most active zones were optimized by automated HPTLC 
(Fig. 3-5). 
 
Fig. 3. TLC of fractions A1-A10 after VLC of DCM extract on a silicagel 60 column under elution with 
chloroform and hexane (20-100 %). 1: UV 366 nm, 2: derivatization with anisaldehyde-sufuric acid. TLC 
mobile phase: CHCl3-EtOAc-MeOH (90+7+3). 
 
Fig. 4. General guideline for optimization of mobile phases in HPTLC (Reich and Schibli, 2006). 
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Fig. 5. HPTLC scanning of fraction A6 at different wavelengths (220, 254, 280, 310, 366, 420 nm). 
The selected zones were extracted by a TLC-MS interface directly into the mass 
spectrometer and the molecular weights were determined (Fig. 6-12). 
 
Fig. 6. HPTLC-MS. 1: interface between pump and mass spectrometer, 2: extraction head, 3: schematic 
function of the extraction head (www.camag.com). 
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Fig. 7. Mass spectrum of zone 1. 
 
 
Fig. 8. Mass spectrum of zone 2. 
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Fig. 9. Mass spectrum of zone 3. 
 
 
Fig. 10. Mass spectrum of zone 4. 
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Fig. 11. Mass spectrum of zone 5. 
 
 
Fig. 12. Mass spectrum of zone 6. 
Supporting information for article 4 
88 
 
The structures of compounds 1 and 6 were elucidated by one and two-dimensional 
1
H and 
13
C NMR spectroscopy and Q-TOF mass spectrometry (Fig. 13-28) 
 
Fig. 13. Q-TOF mass spectrum of compound 1. 
 
 
Fig. 14. Q-TOF mass spectrum of compound 6. 
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Fig. 15. 1H NMR spectrum of compound 1. 
Fig. 16. 13C NMR spectrum of compound 1. 
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Fig. 17. HMBC spectrum of compound 1. 
 
 
Fig. 18. HSQC spectrum of compound 1. 
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Fig. 19. COSY spectrum of compound 1. 
 
Fig. 20. TOCSY spectrum of compound 1. 
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Fig. 21. NOESY spectrum of compound 1. 
 
Fig. 22. 1H NMR spectrum of compound 6. 
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Fig. 23. 13C NMR spectrum of compound 6. 
Fig. 24. HMBC spectrum of compound 6. 
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Fig. 25. HSQC spectrum of compound 6. 
Fig. 26. COSY spectrum of compound 6. 
  
Supporting information for article 4 
95 
 
Fig. 27. TOCSY spectrum of compound 6. 
Fig. 28. NOESY spectrum of compound 6. 
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The IC50 values of DCM extract and compounds 1 and 6 for AChE inhibition were 
determined in the microplate colorimetric assay (Fig. 29). 
 
Fig. 29. AChE inhibition of DCM extract (100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78 µg/ml), compounds 1 
and 6 (80, 40, 20, 10, 5, 2.5, 1.25, 0.63 µg/ml). 
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Additionally, the amounts of these components in galbanum were determined by 
HPLC analyses using external standardization (Fig. 30). 
 
 
Fig. 30. Calibration curves for HPLC-quantification of compounds 1 and 6. 
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Summary 
Cognitive deficits are one of the most common causes of mental deterioration 
such as learning impairment, delayed amnesia and memory problems e.g. in 
Alzheimer’s disease. The enhancement of cholinergic function by inhibition of 
acetylcholinesterase (AChE) is considered as a rational approach for the treatment of 
neurological disorders such as Alzheimer´s disease and senile dementia. During the last 
two decades the use of herbal medicinal substances in dementia therapy has been 
studied well. 
Iran is among those countries with the longest and richest history in Traditional 
Medicine and especially in the use of herbal medicinal preparations. In this thesis 40 
herbal drugs or plant products that are reported in Iranian traditional medicine (ITM) 
or ethnomedicine as sources for the treatment of cognitive disorders were examined. 
In the first step, the bioactivity of polar methanolic and non-polar 
dichloromethane extracts of all selected herbal samples from ITM was studied on AChE 
inhibition by TLC bioautography and in a microplate assay. The most active herbal 
drugs were the seeds from Peganum harmala, the fruit resin from Semecarpus 
anacardium, the gum-resin from Dorema ammoniacum and the oleo gum-resin from 
Ferula gummosa. Those were selected for further study. 
In detailed investigations, the active compounds were identified and isolated using 
several chromatographic techniques such as thin layer chromatography, vacuum liquid 
chromatography, column chromatography, size exclusion chromatography, solid phase 
extraction, high performance liquid chromatography, counter current chromatography 
and automated high performance thin layer chromatography. The structures of the 
active components were characterized by one and two-dimensional 
1
H and 
13
C NMR 
spectroscopy (COSY, TOCSY, HSQC, HMBC, NOESY) and mass spectrometry. The IC50 
values for active compounds were determined by a quantitative colorimetric assay. 
Additionally, the concentrations of active components in the four different sources 
were determined by HPLC analysis. 
The active compounds in the seeds of Peganum harmala were identified as 
harmine and harmaline. From the correlation of IC50 values of the extracts in AChE 
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inhibition with the concentrations of harmaline and harmine in the respective extracts 
can be concluded that these two alkaloids are the major AChE inhibitory compounds in 
Peganum harmala.  
The characterization of the active compounds in the fruit resin of  Semecarpus 
anacardium resulted in 1’,2’-dihydroxy-3’-pentadec-8-enylbenzene and 1’,2’-
dihydroxy-3’-pentadeca-8,11-dienylbenzene. In addition, an in silico study confirmed 
their AChE inhibitory effect. Further experiments showed their selective inhibitory 
activity for AChE versus BChE. The correlation of AChE inhibition with the percentage 
of the active compounds in the fruit resin, can explain their responsibility for the AChE 
inhibition of this resin. 
In the gum-resin of Dorema ammoniacum the active components were 
identified as (2'S,5'S)-2'-ethenyl-5'-(3-hydroxy-6-methyl-4-oxohept-5-en-2-yl)-7-
methoxy-2'-methyl-4H-spiro[chromene-3,1'-cyclopentane]-2,4-dione and (2'S,5'R)-2'-
ethenyl-5'-[(2R,4R)-4-hydroxy-6-methyl-3-oxohept-5-en-2-yl]-7-methoxy-2'-methyl-
4H spiro[chromene-3,1'-cyclopentane]-2,4-dione. The second compound is a new 
natural substance. From the high concentration of these two components in this 
gum-resin can be deduced they are of among the major compounds responsible for 
the AChE inhibitory activity of this drug. 
The structure elucidation of the active substances in the oleo gum-resin of Ferula 
gummosa gave 7-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-2H-chromen-2-one and 7-
(((1R,4aR,6S,8aS)-6-hydroxy-5,5,8a-trimethyl-2-methylenedecahydronaphthalen-
1-yl)methoxy)-2H-chromen-2-one. This is the first report of these two compounds in F. 
gummosa and from the result can be concluded that they are of importance for the 
activity. The study showed that HPTLC-MS/NMR can be considered as a fast method 
for dereplication of natural compounds, when an optimum separation on HPTLC plate 
is provided.  
The AChE inhibition of the isolated compounds from the investigated herbal drugs 
and their IC50 values were reported for the first time in this thesis. The achieved results 
confirmed that the compounds considerably contribute to the effects of these drugs 
and underline the plausibility of their use in the treatment of cognitive deficits in ITM. 
Zusammenfassung 
101 
 
Zusammenfassung 
Kognitive Störungen sind eine der Ursachen von mentalem Abbau, der von 
Symptomen wie Erinnerungsverlust und Gedächnisschwund z.b. im Rahmen der 
Alzheimer-Krankheit begleitet wird. Die Steigerung von cholinergen Funktionen durch 
Inhibierung von Acetylcholinesterase (AChE) stellt eine therapeutische Möglichkeit zur 
Behandlung von neurologischen Störungen wie Alzheimer-Krankheit und Demenz dar. 
In den letzten zwei Jahrzehnten rückte auch der Einsatz traditioneller Heilpflanzen zur 
Therapie von Demenz-Krankheiten in den Mittelpunkt des wissenschaftlichen 
Interesses.  
Der Iran ist eine der Kulturen mit einer langen und reichen Geschichte der 
traditionellen Medizin, und speziell der Pflanzenheilkunde. In dieser Studie wurden 40 
Heilpflanzen bzw. Pflanzenprodukte wie Harze, die in der Iranischen Traditionellen 
Medizin zur Behandlung von kognitiven Störungen eingesetzt wurden, untersucht.  
Zuerst wurden polare methanolische und apolare Dichlormethan-Extrakteaus den 
selektierten Pflanzen hergestellt. Die Aktivität der Extrakte, AChE zu hemmen, wurde 
mittels Dünnschichtchromatographie und in einem Microplate  Assay analysiert.  Die 
stärkste Inhibierungs wurde für Extrakte aus den Samen von Peganum harmalaund aus 
Harzen  von Semecarpus anacardium, Dorema ammoniacum und Ferula gummosa 
festgestellt. Diese vier Ausgangsmaterialien wurden für die weiteren Analysen 
verwendet. Die aktiven Inhaltsstoffe wurden mittels chromatographischer Methoden 
wie Vakuumflüssigchromatographie, Säulenchromatographie, Gel-Permeations-
Chromatographie, Festphasenextraktion, Gegenstromverteilungschromatographie und 
automatisierter HPTLC isoliert. Die Charakterisierung der isolierten bioaktiven 
Komponten erfolgte durch ein- und zwei dimensionale 
1
H and 
13
C NMR Spektroskopie 
(COSY, TOCSY, HSQC, HMBC, NOESY) und Massenpektrometrie. Die Hemmwirkung der 
aktiven  Extrakte und isolierten Verbindungen auf AChE wurde durch die Bestimmung 
der IC50 Werte quantifiziert. Ausserdem wurden die Konzentrationen dieser 
Wirkkomponenten in den einzelnen Drogen mittels validierter HPLC-Verfahren 
bestimmt.  
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In Samen von Peganum harmala wurden die Alkaloide Harmine und Harmaline als 
die aktiven Komponente identifiziert.  Die Korrelation zwischen den IC50 Werten der 
Extrakte und den Konzentrationen der  aktiven Komponenten zeigte, dass die 
Hemmung der AChE durch Peganum harmala überwiegend auf diese zwei Alkaloide 
zurückzuführen ist. 
Im Harz der Früchte von Semecarpus anacardium wurden 1’,2’-dihydroxy-3’-
pentadec-8-enylbenzene und 1’,2’-dihydroxy-3’-pentadeca-8,11-dienylbenzene als 
Komponenten mit inhibitorischer Wirkung auf AchE identifiziert. Dieser Effekt konnte 
zusätzlich durch ein in Silico Experiment bestätigt werden. Weitere Experimente 
zeigten, dass diese Komponenten nur AChE inhibieren, während sie keine Hemmung 
der Butyrylcholinesterase (BchE) bewirkten. Zusätzlich konnte eine Korrelation 
zwischen der AchE Inhibierung und der Konzentration dieser Substanzen im Harz 
nachgewiesen werden. Diese Resultate deuten erstmalig darauf, dass diese zwei 
Substanzen für die AChE Inhibierung durch das Harz der Früchte von Semecarpus 
anacardium hauptverantwortlich sind.   
Im Harz von Dorema ammoniacum wurden 2 Inhaltstoffe (2'S,5'S)-2'-ethenyl-5'-(3-
hydroxy-6-methyl-4-oxohept-5-en-2-yl)-7-methoxy-2'-methyl-4H-spiro[chromene-3,1'-
cyclopentane]-2,4-dione und (2'S,5'R)-2'-ethenyl-5'-[(2R,4R)-4-hydroxy-6-methyl-3-
oxohept-5-en-2-yl]-7-methoxy-2'-methyl-4H-spiro[chromene-3,1'-cyclopentane]-2,4-
dione mit AChE-hemmender Wirkung identifiziert. Der zweite Inhaltstoff ist ein neuer 
Naturstoff, der zum ersten Mal in dieser Arbeit identifiziert werden konnte.  Beide 
Inhaltstoffe waren in relativ hoher Konzentration im Harz enthalten und die 
Korrelation zwischen den Konzentrationen und dem Inhibierungseffekt war wiederum 
ein starkes Indiz dafür, dass diese Inhaltstoffe für die AchE Inhibierung verantwortlich 
sind.  
Aus dem Harz von Ferula gummosa wurden die Komponenten 7-{[(2E)-3,7-
dimethylocta-2,6-dien-1-yl]oxy}-2H-chromen-2-one und 7-(((1R,4aR,6S,8aS)-6-hydroxy-
5,5,8a-trimethyl-2-methylenedecahydronaphthalen-1-yl)methoxy)-2H-chromen-2-one  
isoliert und charakterisiert. Die relativ hohen Konzentrationen dieser Komponenten in 
Korrelation mit der AChE-Inhibierung lassen die Anwendung dieses Harzes in der 
Iranischen traditionellen Medizin plausibel erscheinen. Diese Studie zeigte ausserdem, 
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dass die HPTLC-MS/NMR als eine sehr effiziente Methode zur direkten und schnellen 
Identifizierung von Inhaltstoffen aus komplexen Pflanzenextrakten herangezogen 
werden kann, wobei eine optimierte Trennung  in der HPTLC eine wichtige 
Voraussetzung ist.  
Im Rahmen dieser Dissertation wurde zum ersten Mal die Aktivität der Inhaltstoffe 
von vier Heilpflanzen bzw. Pflanzenprodukten aus der Iranischen Traditionellen 
Medizin auf AChE-Hemmung nachgewiesen. Die Isolierung, Charakterisierung und 
Bestimmung der IC50 Werte dieser Inhaltstoffe wurde erfolgreich durchgeführt. Durch 
diese Arbeit konnte der Einsatz dieser Heilpflanzen in der Iranischen Traditionellen 
Medizin zur Behandlung von kognitiven Störungen wissenschaftlich belegt werden. 
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